$COGT News

Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Advanced Systemic Mastocytosis

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage

Cogent Biosciences, Inc. (COGT) Presents at European Hematology Association (EHA) 2026 Congress - Slideshow

Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14

How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen

Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now?

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

Cogent Biosciences Says FDA Accepts NDA For Bezuclastinib In Combination With Sunitinib For Patients With GIST With PDUFA Target Action Date Of November 30

Assessing Cogent Biosciences (COGT) Valuation After A Strong Year And Recent Share Price Pullback

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

Cogent Biosciences (COGT) Valuation After Wider Q1 Loss And Bezuclastinib Regulatory Progress

HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55

Cogent Biosciences Q1 EPS $(0.53) Beats $(0.56) Estimate

Cogent Biosciences Inc (NASDAQ:COGT) Shows Bullish Technical Breakout Setup with High Scores

Cogent Biosciences Announces That Results From Its Phase 3 PEAK Trial Have Been Selected For Oral Presentation At The 2026 American Society Of Clinical Oncology Annual Meeting, May 29-June 2